United States Biotechnology & Medical Research

Akero Therapeutics Inc (AKRO)

Track

Akero Therapeutics Inc. experienced multiple divestments by key executives throughout September and October 2025. These transactions, primarily structured as planned or proposed sales, involved leadership including the CEO, COO, and CSO. The most recent activity occurred on October 10, 2025, reflecting a consistent pattern of equity liquidation by senior management during this period.
Ticker: AKRO Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Akero Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 10 Oct 2025
Value US$3,062,553.51 | Price 113.80 | Shares 83,338 (+30.9%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-10-14 2025-10-10 PlS Planned sale
3.3
Cheng Andrew

President and CEO

Executive Director
83,338 +30.9%
113.80
US$3,062,554 		83,338 +30.9% 113.80 US$3,062,554
2025-10-09 2025-10-07 PlS Planned sale
4.1
Rolph Timothy

Chief Scientific Officer

Officer
77,941 -29.8%
449.07
US$2,761,343 		77,941 -29.8% 449.07 US$2,761,343
2025-10-09 2025-10-07 PlS Planned sale
4.1
Rolph Timothy

Chief Scientific Officer

Officer
21,281 +47.3%
321.29
US$2,152,867 		21,281 +47.3% 321.29 US$2,152,867
2025-10-07 2025-10-07 PrS Proposed sale
4.1
Timothy Rolph

Officer

Officer
56,369
46.04
US$2,595,229 		56,369 46.04 US$2,595,229
2025-10-03 2025-10-01 PlS Planned sale
1.8
Young Jonathan

Chief Operating Officer

Officer
4,201 -2.1%
47.98
US$201,581 		4,201 -2.1% 47.98 US$201,581
2025-10-03 2025-10-01 PlS Planned sale
1.8
Young Jonathan

Chief Operating Officer

Officer
8,299 -4.0%
47.64
US$395,398 		8,299 -4.0% 47.64 US$395,398
2025-09-12 2025-09-11 S Sale
1.8
Young Jonathan

Chief Operating Officer

Officer
586 -0.3%
43.02
US$25,210 		586 -0.3% 43.02 US$25,210
2025-09-12 2025-09-11 S Sale
3.8
White William Richard

Chief Financial Officer

Officer
659 -1.1%
43.02
US$28,350 		659 -1.1% 43.02 US$28,350
2025-09-12 2025-09-11 S Sale
3.3
Cheng Andrew

President and CEO

Executive Director
1,796 -0.4%
43.02
US$77,264 		1,796 -0.4% 43.02 US$77,264
2025-09-12 2025-09-11 S Sale
4.0
Yale Catriona

Chief Development Officer

Officer
659 -0.7%
43.02
US$28,350 		659 -0.7% 43.02 US$28,350
2025-09-12 2025-09-11 S Sale
4.1
Rolph Timothy

Chief Scientific Officer

Officer
553 -0.3%
43.02
US$23,790 		553 -0.3% 43.02 US$23,790
2025-09-12 2025-09-10 PlS Planned sale
3.3
Cheng Andrew

President and CEO

Executive Director
158 -0.0%
44.62
US$7,050 		158 -0.0% 44.62 US$7,050
2025-09-12 2025-09-10 PlS Planned sale
3.3
Cheng Andrew

President and CEO

Executive Director
7,317 -1.5%
44.00
US$321,911 		7,317 -1.5% 44.00 US$321,911
2025-09-12 2025-09-10 PlS Planned sale
3.3
Cheng Andrew

President and CEO

Executive Director
22,525 -4.5%
42.99
US$968,440 		22,525 -4.5% 42.99 US$968,440
2025-09-10 2025-09-10 PrS Proposed sale
3.3
Andrew Cheng

President, CEO and Director

Non-Executive Director
90,000
44.62
US$4,015,800 		90,000 44.62 US$4,015,800
2025-09-10 2025-09-08 PlS Planned sale
4.1
Rolph Timothy

Chief Scientific Officer

Officer
34 -0.0%
44.88
US$1,526 		34 -0.0% 44.88 US$1,526
2025-09-10 2025-09-08 PlS Planned sale
4.1
Rolph Timothy

Chief Scientific Officer

Officer
12,466 -6.9%
44.17
US$550,611 		12,466 -6.9% 44.17 US$550,611
2025-09-04 2025-09-02 PlS Planned sale
1.8
Young Jonathan

Chief Operating Officer

Officer
61 -0.0%
47.58
US$2,902 		61 -0.0% 47.58 US$2,902
2025-09-04 2025-09-02 PlS Planned sale
1.8
Young Jonathan

Chief Operating Officer

Officer
2,739 -1.4%
47.14
US$129,106 		2,739 -1.4% 47.14 US$129,106
2025-09-04 2025-09-02 PlS Planned sale
1.8
Young Jonathan

Chief Operating Officer

Officer
9,700 -4.6%
45.78
US$444,027 		9,700 -4.6% 45.78 US$444,027
2025-08-13 2025-08-12 PlS Planned sale
1.8
Young Jonathan

Chief Operating Officer

Officer
1,349 -0.7%
48.32
US$65,189 		1,349 -0.7% 48.32 US$65,189
2025-08-13 2025-08-12 PlS Planned sale
1.8
Young Jonathan

Chief Operating Officer

Officer
11,151 -5.3%
47.72
US$532,137 		11,151 -5.3% 47.72 US$532,137
2025-08-12 2025-08-12 PrS Proposed sale
1.8
Jonathan Young

Officer

Officer
50,000
48.28
US$2,414,000 		50,000 48.28 US$2,414,000
2025-08-12 2025-08-12 PrS Proposed sale
3.6
JANE HENDERSON

Director

Non-Executive Director
3,000
47.46
US$142,372 		3,000 47.46 US$142,372
2025-08-12 2025-08-12 S Sale
3.6
Henderson Jane
Non-Executive Director
3,000 -24.2%
47.46
US$142,371 		3,000 -24.2% 47.46 US$142,371
2025-08-13 2025-08-11 PlS Planned sale
3.3
Cheng Andrew

President and CEO

Executive Director
400 -0.1%
49.44
US$19,774 		400 -0.1% 49.44 US$19,774
2025-08-13 2025-08-11 PlS Planned sale
3.3
Cheng Andrew

President and CEO

Executive Director
18,805 -3.7%
48.87
US$918,906 		18,805 -3.7% 48.87 US$918,906
2025-08-13 2025-08-11 PlS Planned sale
3.3
Cheng Andrew

President and CEO

Executive Director
10,795 -2.1%
48.07
US$518,916 		10,795 -2.1% 48.07 US$518,916
2025-08-07 2025-08-05 PlS Planned sale
4.1
Rolph Timothy

Chief Scientific Officer

Officer
6,962 -4.0%
49.49
US$344,577 		6,962 -4.0% 49.49 US$344,577
2025-08-07 2025-08-05 PlS Planned sale
4.1
Rolph Timothy

Chief Scientific Officer

Officer
5,538 -3.1%
49.07
US$271,722 		5,538 -3.1% 49.07 US$271,722
2025-07-18 2025-07-16 PlS Planned sale
4.0
Yale Catriona

Chief Development Officer

Officer
1,342 -1.4%
53.47
US$71,762 		1,342 -1.4% 53.47 US$71,762
2025-07-18 2025-07-16 PlS Planned sale
4.0
Yale Catriona

Chief Development Officer

Officer
8,658 -8.5%
52.87
US$457,705 		8,658 -8.5% 52.87 US$457,705
2025-07-11 2025-07-10 PlS Planned sale
3.3
Cheng Andrew

President and CEO

Executive Director
15,314 -2.9%
51.73
US$792,224 		15,314 -2.9% 51.73 US$792,224
2025-07-11 2025-07-10 PlS Planned sale
3.3
Cheng Andrew

President and CEO

Executive Director
14,686 -2.7%
50.57
US$742,671 		14,686 -2.7% 50.57 US$742,671
2025-07-09 2025-07-07 PlS Planned sale
4.1
Rolph Timothy

Chief Scientific Officer

Officer
41 -0.0%
52.62
US$2,157 		41 -0.0% 52.62 US$2,157
2025-07-09 2025-07-07 PlS Planned sale
4.1
Rolph Timothy

Chief Scientific Officer

Officer
1,825 -1.1%
52.00
US$94,893 		1,825 -1.1% 52.00 US$94,893
2025-07-09 2025-07-07 PlS Planned sale
4.1
Rolph Timothy

Chief Scientific Officer

Officer
10,634 -5.9%
50.93
US$541,611 		10,634 -5.9% 50.93 US$541,611
2025-07-07 2025-07-07 PrS Proposed sale
4.1
Timothy Rolph

Officer

Officer
56,250
51.85
US$2,916,563 		56,250 51.85 US$2,916,563
2025-07-03 2025-07-01 PlS Planned sale
3.2
Lamy Patrick

Senior VP, Commercial Strategy

Officer
2,000 -6.3%
52.88
US$105,760 		2,000 -6.3% 52.88 US$105,760
2025-07-01 2025-07-01 PrS Proposed sale
3.2
PATRICK D LAMY

Officer

Officer
2,000
53.36
US$106,720 		2,000 53.36 US$106,720
2025-06-20 2025-06-20 S Sale
3.2
Lamy Patrick

Senior VP, Commercial Strategy

Officer
875 -2.7%
54.59
US$47,766 		875 -2.7% 54.59 US$47,766
2025-06-20 2025-06-18 S Sale
4.0
Yale Catriona

Chief Development Officer

Officer
1,633 -1.8%
54.84
US$89,554 		1,633 -1.8% 54.84 US$89,554
2025-06-20 2025-06-18 S Sale
3.8
White William Richard

Chief Financial Officer

Officer
1,634 -2.8%
54.84
US$89,609 		1,634 -2.8% 54.84 US$89,609
2025-06-20 2025-06-18 S Sale
1.8
Young Jonathan

Chief Operating Officer

Officer
1,453 -0.7%
54.84
US$79,683 		1,453 -0.7% 54.84 US$79,683
2025-06-20 2025-06-18 S Sale
2.9
Gangloff Scott A.

Chief Technology Officer

Officer
848 -3.5%
54.84
US$46,504 		848 -3.5% 54.84 US$46,504
2025-06-20 2025-06-18 S Sale
4.1
Rolph Timothy

Chief Scientific Officer

Officer
1,129 -0.7%
54.84
US$61,914 		1,129 -0.7% 54.84 US$61,914
2025-06-20 2025-06-18 S Sale
3.3
Cheng Andrew

President and CEO

Executive Director
6,620 -1.2%
54.84
US$363,041 		6,620 -1.2% 54.84 US$363,041
2025-06-20 2025-06-16 PlS Planned sale
4.0
Yale Catriona

Chief Development Officer

Officer
895 -1.0%
55.52
US$49,690 		895 -1.0% 55.52 US$49,690
2025-06-20 2025-06-16 PlS Planned sale
4.0
Yale Catriona

Chief Development Officer

Officer
2,895 -3.0%
54.80
US$158,643 		2,895 -3.0% 54.80 US$158,643
2025-06-20 2025-06-16 PlS Planned sale
4.0
Yale Catriona

Chief Development Officer

Officer
6,210 -6.1%
53.78
US$333,974 		6,210 -6.1% 53.78 US$333,974
2025-06-20 2025-06-16 PlS Planned sale
3.2
Lamy Patrick

Senior VP, Commercial Strategy

Officer
500 -1.5%
55.09
US$27,546 		500 -1.5% 55.09 US$27,546
2025-06-20 2025-06-16 PlS Planned sale
3.2
Lamy Patrick

Senior VP, Commercial Strategy

Officer
1,500 -4.3%
53.82
US$80,726 		1,500 -4.3% 53.82 US$80,726
2025-06-12 2025-06-10 S Sale
1.8
Young Jonathan

Chief Operating Officer

Officer
2,493 -1.2%
53.99
US$134,605 		2,493 -1.2% 53.99 US$134,605
2025-06-12 2025-06-10 S Sale
3.8
White William Richard

Chief Financial Officer

Officer
2,804 -4.5%
54.00
US$151,402 		2,804 -4.5% 54.00 US$151,402
2025-06-12 2025-06-10 S Sale
4.1
Rolph Timothy

Chief Scientific Officer

Officer
2,358 -1.4%
54.00
US$127,323 		2,358 -1.4% 54.00 US$127,323
2025-06-12 2025-06-10 S Sale
3.2
Lamy Patrick

Senior VP, Commercial Strategy

Officer
919 -2.7%
54.00
US$49,625 		919 -2.7% 54.00 US$49,625
2025-06-12 2025-06-10 S Sale
3.3
Cheng Andrew

President and CEO

Executive Director
7,837 -1.4%
53.99
US$423,151 		7,837 -1.4% 53.99 US$423,151
2025-06-12 2025-06-10 PlS Planned sale
3.3
Cheng Andrew

President and CEO

Executive Director
15,158 -2.6%
54.35
US$823,883 		15,158 -2.6% 54.35 US$823,883
2025-06-12 2025-06-10 PlS Planned sale
3.3
Cheng Andrew

President and CEO

Executive Director
14,842 -2.5%
53.76
US$797,906 		14,842 -2.5% 53.76 US$797,906
2025-06-12 2025-06-10 S Sale
4.0
Yale Catriona

Chief Development Officer

Officer
2,803 -2.9%
54.00
US$151,351 		2,803 -2.9% 54.00 US$151,351
2025-06-09 2025-06-06 PlS Planned sale
4.1
Rolph Timothy

Chief Scientific Officer

Officer
25,000 -12.8%
55.04
US$1,376,000 		25,000 -12.8% 55.04 US$1,376,000
2025-06-09 2025-06-05 PlS Planned sale
4.1
Rolph Timothy

Chief Scientific Officer

Officer
3,150 -1.8%
53.84
US$169,596 		3,150 -1.8% 53.84 US$169,596
2025-06-09 2025-06-05 PlS Planned sale
4.1
Rolph Timothy

Chief Scientific Officer

Officer
9,350 -5.1%
53.37
US$499,038 		9,350 -5.1% 53.37 US$499,038
2025-06-04 2025-06-02 PlS Planned sale
3.2
Lamy Patrick

Senior VP, Commercial Strategy

Officer
100 -0.3%
51.04
US$5,104 		100 -0.3% 51.04 US$5,104
2025-06-04 2025-06-02 PlS Planned sale
3.2
Lamy Patrick

Senior VP, Commercial Strategy

Officer
3,300 -8.9%
50.46
US$166,515 		3,300 -8.9% 50.46 US$166,515
2025-06-04 2025-06-02 PlS Planned sale
3.2
Lamy Patrick

Senior VP, Commercial Strategy

Officer
600 -1.6%
49.40
US$29,639 		600 -1.6% 49.40 US$29,639
2025-05-23 2025-05-22 PlS Planned sale
3.2
Lamy Patrick

Senior VP, Commercial Strategy

Officer
4,000 -10.7%
50.00
US$200,000 		4,000 -10.7% 50.00 US$200,000
2025-05-22 2025-05-22 PrS Proposed sale
3.2
PATRICK D LAMY

Officer

Officer
10,000
48.35
US$483,500 		10,000 48.35 US$483,500
2025-05-19 2025-05-15 PlS Planned sale
4.0
Yale Catriona

Chief Development Officer

Officer
4,384 -4.4%
39.91
US$174,948 		4,384 -4.4% 39.91 US$174,948
2025-05-19 2025-05-15 PlS Planned sale
4.0
Yale Catriona

Chief Development Officer

Officer
2,779 -2.7%
39.46
US$109,659 		2,779 -2.7% 39.46 US$109,659
2025-05-19 2025-05-15 PlS Planned sale
4.0
Yale Catriona

Chief Development Officer

Officer
2,837 -2.7%
38.20
US$108,371 		2,837 -2.7% 38.20 US$108,371
2025-05-15 2025-05-15 PrS Proposed sale
4.0
CATRIONA YALE

Officer

Officer
30,000
37.88
US$1,136,400 		30,000 37.88 US$1,136,400
2025-05-13 2025-05-12 PlS Planned sale
3.3
Cheng Andrew

President and CEO

Executive Director
22,800 -3.7%
41.63
US$949,255 		22,800 -3.7% 41.63 US$949,255
2025-05-13 2025-05-12 PlS Planned sale
3.3
Cheng Andrew

President and CEO

Executive Director
7,200 -1.2%
41.00
US$295,200 		7,200 -1.2% 41.00 US$295,200
2025-05-12 2025-05-12 PrS Proposed sale
3.3
Andrew Cheng

Officer

Officer
120,000
39.85
US$4,782,000 		120,000 39.85 US$4,782,000
Explore more

More insider trading research around Akero Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America